We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
You're enjoying temporary access to this content

Welcome to PracticeUpdate! We hope you are enjoying temporary access to this content. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

featured
Published in Oncology

Expert Opinion / Interview · June 24, 2021

Weekly Paclitaxel, Carboplatin, and Cetuximab as Induction Therapy for Metastatic or Relapsed Head and Neck Cancer

Interview with
Barbara Burtness MD

 

This multimedia content was independently funded and produced by PracticeUpdate. Publication does not constitute representation by PracticeUpdate that the data presented are correct or sufficient to support the conclusions reached.

Further Reading